A Phase 1, Randomized Double-Blind, Placebo-Controlled, Single Ascending Dose Safety, Tolerability, and Pharmacokinetics Study of SAB-301 in Healthy Adults

Trial Profile

A Phase 1, Randomized Double-Blind, Placebo-Controlled, Single Ascending Dose Safety, Tolerability, and Pharmacokinetics Study of SAB-301 in Healthy Adults

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 16 May 2017

At a glance

  • Drugs MERS monoclonal antibody (Primary)
  • Indications Middle East respiratory syndrome coronavirus
  • Focus Adverse reactions
  • Most Recent Events

    • 09 May 2017 Planned primary completion date changed from 30 Apr 2017 to 10 Apr 2018.
    • 24 Jan 2017 Status changed from recruiting to active, no longer recruiting.
    • 24 Aug 2016 According to SAB Biotherapeutics media release, this trial will be conducted by the National Institutes of Health (NIH).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top